Ferrante A, Mocatta F, Goh D H
Int Arch Allergy Appl Immunol. 1986;81(3):284-7. doi: 10.1159/000234148.
IgE and IgG antibodies to bee venom were measured in sera of patients receiving bee venom immunotherapy. All patients selected for therapy had suffered severe reactions to bee stings. The results showed that within 2-3 months from the commencement of immunotherapy there was a marked rise in IgG antibodies and a slight but not significant rise in IgE antibodies. After this period, the IgE antibody level began to fall and was about one third of the pre-treatment level by the second to third year. The IgG antibody level began to decline from its increased level after 9-10 months but remained above the pre-treatment level even after 2 years. All of the patients who had subsequently been accidentally stung after reaching the maintenance dosage of bee venom allergen showed no severe reactions. A small group of non-treated patients of the same category as those receiving therapy did not show a rise but a decline in the level of IgG antibodies. However, like the treated group, they showed a significant decrease in IgE antibodies. Thus one of the main benefits of bee venom immunotherapy is the build-up of a high concentrations of IgG antibodies, and this may be the critical factor in the protection against bee venom allergy.
在接受蜂毒免疫疗法的患者血清中检测了针对蜂毒的IgE和IgG抗体。所有被选来接受治疗的患者都曾对蜂蜇有过严重反应。结果显示，在免疫疗法开始后的2至3个月内，IgG抗体显著升高，IgE抗体略有升高但不显著。在此之后，IgE抗体水平开始下降，到第二至第三年时约为治疗前水平的三分之一。IgG抗体水平在9至10个月后从升高水平开始下降，但即使在2年后仍高于治疗前水平。所有在达到蜂毒过敏原维持剂量后随后意外被蜇的患者均未出现严重反应。一小群与接受治疗的患者属于同一类别的未治疗患者，其IgG抗体水平未升高反而下降。然而，与治疗组一样，他们的IgE抗体显著下降。因此，蜂毒免疫疗法的主要益处之一是产生高浓度的IgG抗体，这可能是预防蜂毒过敏的关键因素。
